MAM
CHRS icon

Martingale Asset Management’s Coherus Oncology CHRS Stock Holding History

Martingale Asset Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-24,100
Closed -$175K – 828
2022
Q2 		$175K Buy
+24,100
New +$210K ﹤0.01% 813
2020
Q2 		– Sell
-42,712
Closed -$693K – 1027
2020
Q1 		$693K Buy
+42,712
New +$789K 0.01% 752

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Martingale Asset Management's CHRS Position: Q3 2022 in Review

Martingale Asset Management sold out of Coherus Oncology (CHRS) in Q3 2022, closing a stake of 24,100 shares — an estimated $175K sold.

Martingale Asset Management first reported a position in CHRS in Q1 2020 and held it in 2 quarters. The position peaked at $693K in Q1 2020. 174 funds tracked by Wall St. Rank hold CHRS as of Q3 2022.

  • Martingale Asset Management reported no remaining Coherus Oncology position as of Q3 2022 after selling out during the quarter.
  • Martingale Asset Management sold 24,100 Coherus Oncology shares in Q3 2022, an estimated $175K.
  • Martingale Asset Management first reported a position in Coherus Oncology in Q1 2020 and held it in 2 quarters.
  • Martingale Asset Management's Coherus Oncology position peaked at $693K in Q1 2020.
  • 174 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2022.

Based on Martingale Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.